Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACBFF Aurora Cannabis	$4.78 +1.3%	$4.67	$2.20 ▼ $12.53	$4.59B	N/A	4.22 million shs	1.03 million shs
CYTK Cytokinetics	$38.34 +0.8%	$35.68	$29.31 ▼ $59.39	$4.59B	0.64	1.74 million shs	1.55 million shs
EVTCY Evotec	$3.54 -0.8%	$4.03	$14.22 ▼ $26.57	$1.17B	0.98	2,407 shs	71,065 shs
VKTX Viking Therapeutics	$26.00 +1.3%	$31.17	$18.92 ▼ $81.73	$2.92B	0.67	4.73 million shs	10.55 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACBFF Aurora Cannabis	-0.84%	-14.65%	+0.43%	-14.03%	-25.55%
CYTK Cytokinetics	+1.96%	-1.73%	+0.93%	+24.59%	-32.75%
EVTCY Evotec	-1.11%	-6.30%	-3.25%	-11.41%	+11.56%
VKTX Viking Therapeutics	-0.12%	-36.23%	-20.06%	-4.89%	-60.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACBFF Aurora Cannabis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	3.7434 of 5 stars	3.5	1.0	0.0	4.6	3.1	0.8	0.0
EVTCY Evotec	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	4.0243 of 5 stars	3.5	1.0	0.0	4.7	2.8	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACBFF Aurora Cannabis	0.00	N/A	N/A	N/A
CYTK Cytokinetics	2.93	Moderate Buy	$71.58	86.71% Upside
EVTCY Evotec	0.00	N/A	N/A	N/A
VKTX Viking Therapeutics	3.00	Buy	$86.92	234.32% Upside

Current Analyst Ratings Breakdown

Latest EVTCY, ACBFF, CYTK, and VKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00
8/8/2025	CYTK Cytokinetics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $77.00
7/30/2025	CYTK Cytokinetics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform
7/24/2025	VKTX Viking Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Strong-Buy ➝ Strong-Buy	$125.00 ➝ $122.00
7/24/2025	VKTX Viking Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$31.00 ➝ $38.00
6/25/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00
6/9/2025	CYTK Cytokinetics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$71.00 ➝ $53.00
5/29/2025	CYTK Cytokinetics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$103.00 ➝ $84.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACBFF Aurora Cannabis	N/A	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	$18.47M	248.39	N/A	N/A	($3.08) per share	-12.45
EVTCY Evotec	$572.16M	2.04	$0.03 per share	105.53	$2.52 per share	1.40
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$7.07 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACBFF Aurora Cannabis	N/A	$0.12	39.83	∞	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	-$589.53M	-$5.10	N/A	N/A	N/A	-707.17%	N/A	-45.52%	11/5/2025 (Estimated)
EVTCY Evotec	$7.14M	$0.41	8.63	∞	N/A	20.85%	16.02%	7.81%	N/A
VKTX Viking Therapeutics	-$109.96M	-$1.53	N/A	N/A	N/A	N/A	-19.98%	-19.38%	10/22/2025 (Estimated)

Latest EVTCY, ACBFF, CYTK, and VKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	CYTK Cytokinetics	-$1.34	-$1.12	+$0.22	-$1.12	$1.95 million	$66.77 million
7/23/2025	Q2 2025	VKTX Viking Therapeutics	-$0.44	-$0.58	-$0.14	-$0.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACBFF Aurora Cannabis	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
EVTCY Evotec	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACBFF Aurora Cannabis	N/A	N/A	N/A
CYTK Cytokinetics	N/A	6.76	6.76
EVTCY Evotec	0.53	2.57	2.50
VKTX Viking Therapeutics	N/A	25.86	25.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACBFF Aurora Cannabis	N/A
CYTK Cytokinetics	N/A
EVTCY Evotec	N/A
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
ACBFF Aurora Cannabis	N/A
CYTK Cytokinetics	2.70%
EVTCY Evotec	N/A
VKTX Viking Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACBFF Aurora Cannabis	1,340	960.96 million	N/A	Not Optionable
CYTK Cytokinetics	250	119.66 million	116.43 million	Optionable
EVTCY Evotec	4,200	330.22 million	N/A	Not Optionable
VKTX Viking Therapeutics	20	112.45 million	107.84 million	Optionable

EVTCY, ACBFF, CYTK, and VKTX Headlines

Recent News About These Companies

Viking Therapeutics (VKTX) Down 23.4% Since Last Earnings Report: Can It Rebound?

3 hours ago | msn.com

Viking Therapeutics (VKTX) Reports Increased Net Losses For Second Quarter

3 hours ago | finance.yahoo.com

Here's Why Shares in Viking Therapeutics Crashed This Week

August 22 at 11:35 AM | msn.com

Viking Therapeutics (VKTX) Rebounds on Bargain-Hunting. Are You Missing Out?

August 21 at 2:13 PM | insidermonkey.com

A Closer Look at Viking Therapeutics's Options Market Dynamics

August 21 at 1:13 PM | benzinga.com

Post Obesity Pill Results Reveal: Buy, Sell or Hold VKTX Stock?

August 21 at 1:06 PM | zacks.com

Viking Therapeutics (NASDAQ:VKTX) Shares Gap Down - Time to Sell?

August 21 at 12:45 PM | marketbeat.com

HC Wainwright Reiterates Buy Rating for Viking Therapeutics (NASDAQ:VKTX)

August 21 at 11:56 AM | marketbeat.com

Viking Therapeutics Sees Unusually High Options Volume (NASDAQ:VKTX)

August 21 at 11:17 AM | marketbeat.com

Is Beaten-Down Viking Therapeutics Stock a Buy on the Dip?

August 21 at 5:24 AM | fool.com

Steward Partners Investment Advisory LLC Acquires 13,626 Shares of Viking Therapeutics, Inc. $VKTX

August 21 at 4:43 AM | marketbeat.com

Viking Therapeutics' (VKTX) Buy Rating Reiterated at HC Wainwright

August 21 at 2:29 AM | americanbankingnews.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Recommendation of "Buy" by Analysts

August 21 at 2:38 AM | marketbeat.com

Viking Therapeutics: Panic Creates Opportunity

August 20 at 9:02 PM | seekingalpha.com

Here's Why Viking Therapeutics Bounced Back Today

August 20 at 2:03 PM | fool.com

Viking Therapeutics (VKTX) Slashes 42% on Huge Clinical Study Dropout Rate

August 20 at 1:30 PM | insidermonkey.com

Viking Therapeutics' Stock Tanks on Mixed Data From Obesity Pill Study

August 20 at 12:46 PM | zacks.com

Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?

August 20 at 10:31 AM | zacks.com

Viking Therapeutics: What's Happening With VKTX Stock?

August 20 at 10:03 AM | forbes.com

Viking Therapeutics shares tumble after obesity drug trial disappoints

August 20 at 3:32 AM | proactiveinvestors.co.uk

Vanguard Group Inc. Sells 8,184 Shares of Viking Therapeutics, Inc. $VKTX

August 20 at 3:17 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVTCY, ACBFF, CYTK, and VKTX Company Descriptions

Aurora Cannabis OTCMKTS:ACBFF

$4.78 +0.06 (+1.27%)

As of 08/21/2025

Aurora Cannabis Inc is a Canada-based company engaged in the production and distribution of medical cannabis. The Company is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, home cultivation, wholesale and retail distribution. The Company's purpose-built facilities, which integrate technologies across all processes, are defined by automation and customization. The Company has a funded capacity of more than 500,000 kilograms per year, as well as sales and operations in more than 10 countries worldwide.

Cytokinetics NASDAQ:CYTK

$38.34 +0.29 (+0.76%)

Closing price 04:00 PM Eastern

Extended Trading

$38.34 0.00 (0.00%)

As of 05:45 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Evotec OTCMKTS:EVTCY

$3.54 -0.03 (-0.84%)

As of 08/21/2025

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Viking Therapeutics NASDAQ:VKTX

$26.00 +0.34 (+1.33%)

Closing price 04:00 PM Eastern

Extended Trading

$26.00 +0.00 (+0.02%)

As of 07:20 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time